NeuroOne CBO files initial insider ownership

NEUROONE MEDICAL TECHNOLOGIES Corp executive David J. Wambeke, the company’s Chief Business Officer, filed an initial Form 3 reporting his beneficial ownership in the company.

Rhea-AI Filing Summary

NEUROONE MEDICAL TECHNOLOGIES Corp executive David J. Wambeke, the company’s Chief Business Officer, filed an initial Form 3 reporting his beneficial ownership in the company. The filing does not list any insider buy or sell transactions; it simply establishes his status as a reporting officer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the NEUROONE (NMTC) Form 3 filing for David J. Wambeke show?

The Form 3 filing shows that David J. Wambeke, Chief Business Officer of NEUROONE MEDICAL TECHNOLOGIES Corp, has reported his beneficial ownership status as an insider. It is an initial ownership statement and does not list any specific share transactions.

Did David J. Wambeke buy or sell NEUROONE (NMTC) shares in this Form 3?

No, this Form 3 does not report any purchases or sales of NEUROONE MEDICAL TECHNOLOGIES Corp shares by David J. Wambeke. It only establishes his position as a reporting insider and discloses his beneficial ownership status without detailing transactions.

Who is the insider named in NEUROONE (NMTC)’s latest Form 3?

The insider named is David J. Wambeke, who serves as Chief Business Officer of NEUROONE MEDICAL TECHNOLOGIES Corp. The filing identifies his role as an officer and records his initial beneficial ownership as required for company insiders under SEC rules.

Why did NEUROONE (NMTC) file a Form 3 for David J. Wambeke?

A Form 3 is required when someone becomes an insider of a public company. NEUROONE MEDICAL TECHNOLOGIES Corp filed this Form 3 because David J. Wambeke, its Chief Business Officer, must report his beneficial ownership when he attains reporting person status.

Does the NEUROONE (NMTC) Form 3 for David J. Wambeke indicate major transactions?

The Form 3 does not indicate any major transactions. It records David J. Wambeke’s beneficial ownership status as Chief Business Officer of NEUROONE MEDICAL TECHNOLOGIES Corp, but shows no insider buying, selling, or other share transactions in this specific filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 08:39 AM EST Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wambeke David J.

(Last) (First) (Middle)

7599 ANAGRAM DRIVE

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/01/2026

3. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Emily Johns, by Power of Attorney	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.